☰

Erik Cederfjäll, Ph.D. - Publications

Affiliations: 
2008-2014 B.R.A.I.N.S. Unit Lund University, Lund, Skåne län, Sweden 
 2015-2017 Molecules - Signaling - Development Max Planck Institute of Neurobiology, Jupiter, FL, United States 
Area:
Parkinson's disease | Gene therapy
Tree Info Grants Similar researchers PubMed Report error

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Del Toro D, Ruff T, Cederfjäll E, Villalba A, Seyit-Bremer G, Borrell V, Klein R. Regulation of Cerebral Cortex Folding by Controlling Neuronal Migration via FLRT Adhesion Molecules. Cell. 169: 621-635.e16. PMID 28475893 DOI: 10.1016/J.Cell.2017.04.012  0.492
2016 Kirik D, Cederfjäll E, Halliday G, Petersén Å. Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease. PMID 27616425 DOI: 10.1016/J.Nbd.2016.09.008  0.577
2015 Cederfjäll E, Broom L, Kirik D. Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 896-906. PMID 25592335 DOI: 10.1038/Mt.2015.8  0.592
2013 Cederfjäll E, Nilsson N, Sahin G, Chu Y, Nikitidou E, Björklund T, Kordower JH, Kirik D. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Scientific Reports. 3: 2157. PMID 23831692 DOI: 10.1038/Srep02157  0.522
2012 Cederfjäll E, Sahin G, Kirik D, Björklund T. Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1315-26. PMID 22294150 DOI: 10.1038/Mt.2012.1  0.599
2012 Cederfjäll E, Sahin G, Kirik D. Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain. Neurobiology of Disease. 48: 222-7. PMID 22048069 DOI: 10.1016/J.Nbd.2011.10.017  0.589
2010 Björklund T, Cederfjäll EA, Kirik D. Gene therapy for dopamine replacement. Progress in Brain Research. 184: 221-35. PMID 20887878 DOI: 10.1016/S0079-6123(10)84012-9  0.558
2010 Björklund T, Carlsson T, Cederfjäll EA, Carta M, Kirik D. Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain : a Journal of Neurology. 133: 496-511. PMID 20129936 DOI: 10.1093/Brain/Awp314  0.594
Show low-probability matches.